Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies

Leukemia volume 14, pages 2–8 (2000)Cite this article

Abstract

To guide development of new clinical strategies, a review of recent investigations in the pathobiology of MDS was performed. Articles were identified through a Medline search. Studies, including reviews, are cited in the references. A multistep pathogenesis is proposed. (1) Targeted injury or mutation within hemopoietic stem cells may be followed by an immunologic response adversely affecting progenitor survival. (2) Accelerated proliferation and premature death of marrow cells is amplified by apoptogenic cytokines (TNF-α, Fas ligand). (3) Establishment of an abnormal clone associated with telomere shortening. (4) Disease progression associated with loss of tumor suppressor activity. Opportunities for therapeutic interventions are possible at each step. Comparisons between the proposed pathogenesis of MDS and severe aplastic anemia (SAA) are also presented.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Greenberg PL, Nichols WC, Schrier SL . Granulopoiesis in acute myeloid leukemia and preleukemia New Engl J Med 1971 22: 1225–1232

    Article  Google Scholar 

  2. Rosati S, Anastasi J, Vardiman J . Recurring diagnostic problems in the pathology of the myelodysplastic syndromes Semin Hematol 1996 33: 111–126

    CAS  PubMed  Google Scholar 

  3. Asano H, Ohashi H, Ichihara M, Kinoshita T, Murate T, Kobayashi M, Saito H, Hotta T . Evidence for nonclonal hematopoietic progenitor cell populations in bone marrow of patients with myelodysplastic syndromes Blood 1994 84: 588–594

    CAS  PubMed  Google Scholar 

  4. Delforge M, Demuynck H, Vandenberghe P, Verhoef G, Zachée P, Van Duppen V, Marijnen P, Van den Berghe H, Boogaerts M . Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes Blood 1995 86: 3660–3667

    CAS  PubMed  Google Scholar 

  5. Delforge M, Demuynck H, Verhoef G, Vandenberghe P, Zachée P, Maertens J, Duppen VV, Boogaerts MA . Patients with high risk myelodysplastic syndrome can have polyclonal or clonal haemopoiesis in complete haematological remission Br J Haematol 1998 102: 486–494

    Article  CAS  PubMed  Google Scholar 

  6. List AF, Jacobs A . Pathogenesis and biology of myelodysplasia Semin Oncol 1992 29: 14–24

    Google Scholar 

  7. Sanz GF, Sanz MA, Vallespi T . Etiopathogeny, prognosis and therapy of myelodysplastic syndromes Hematol Cell Ther 1997 39: 277–294

    Article  CAS  PubMed  Google Scholar 

  8. Gallagher A, Darley RL, Padua R . The molecular basis of myelodysplastic syndromes Haematologica 1997 82: 191–204

    CAS  PubMed  Google Scholar 

  9. Aul C, Bowen DT, Yoshida Y . Pathogenesis, etiology and epidemiology of myelodysplastic syndromes Haematologica 1998 83: 71–86

    CAS  PubMed  Google Scholar 

  10. West RR, Stafford DA, Farrow A, Jacobs A . Occupational and environmental exposures and myelodysplasia: a case–control study Leukemia Res 1995 19: 127–139

    Article  CAS  Google Scholar 

  11. Nisse C, Grandbastien B, Brizard A, Hebbar M, Haguenoer JM, Fenaux P . Myelodysplastic syndromes (MDS) and exposure to occupational or environmental hazards: a case–control study Blood 1997 90: (Suppl. 1) 518a (Abstr.)

    Google Scholar 

  12. Rigolin GM, Cuneo A, Roberti MG, Bardi A, Bigoni R, Piva N, Minotto C, Agostini P, Angeli CD, Senno LD . Exposure to myelotoxic agents and myelodysplasia: case–control study and correlation with clinobiologic findings Br J Haematol 1998 103: 189–197

    Article  CAS  PubMed  Google Scholar 

  13. Larson LA, Wang Y, Banerjee M, Wiemels J, Hartford C, Le Beau MM, Smith MT . Prevalence of the inactivating609C->T polymorphism in the NAD(P)H: quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia Blood 1999 94: 803–807

    CAS  PubMed  Google Scholar 

  14. Takaku S, Takaku F . Natural killer cell activity and preleukaemia Lancet 1981 2: 1178

    Article  CAS  PubMed  Google Scholar 

  15. List AF, Glinsmann-Gibson B, Spier C, Taetle R . In vitro and in vivo response to cyclosporin-A in myelodysplastic syndromes (MDS): identification of a hypocellular subset responsive to immune suppression Blood 1992 80: (Suppl. 1) 28a (Abstr.)

    Google Scholar 

  16. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ . Hematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vβ profiles Br J Haematol 1998 102: 1314–1322

    Article  CAS  PubMed  Google Scholar 

  17. Van Kamp H, Fibbe WE, Jansen RPM, van der Keur M, de Graaff E, Willemze R, Landegent JE . Clonal involvement of granulocytes and monocytes, but not of T and B lymphocytes and natural killer cells in patients with myelodysplasia: analysis by X-linked restriction fragment length polymorphisms and polymerase chain reaction of the phosphoglycerate kinase gene Blood 1992 80: 1774–1780

    CAS  PubMed  Google Scholar 

  18. Hamblin TJ . Immunological abnormalities in myelodysplastic syndromes Semin Hematol 1996 33: 150–162

    CAS  PubMed  Google Scholar 

  19. Tefferi A, Thibodeau SN, Solberg LA . Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms Blood 1990 75: 1770–1773

    CAS  PubMed  Google Scholar 

  20. Kibbelaar RE, van Kamp H, Dreef EJ, de Groot-Swings G, Kluin-Nelemans JC, Beverstock GC, Fibbe WE, Kluin M . Combined immunophenotyping and DNA in situ hybridization to study lineage involvement in patients with myelodysplastic syndromes Blood 1992 79: 1823–1828

    CAS  PubMed  Google Scholar 

  21. Anastasi J, Feng J, Le Beau M, Larson RA, Rowley JD, Vardiman JW . Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion Blood 1993 81: 1580–1585

    CAS  PubMed  Google Scholar 

  22. Kroef MJPL, Fibbe WE, Mout R, Jansen RPM, Haak HL, Wessels JW, Van Kamp H, Willemze R, Landegent JE . Myeloid but not lymphoid cells carry the 5q deletion: polymerase chain reaction analysis of loss of heterozygosity using mini-repeat sequences on highly purified cell fractions Blood 1993 81: 1849–1854

    CAS  PubMed  Google Scholar 

  23. Sulecki M, Shadduck RK, Zeigler Z . Anti-thymocyte globulin for hypoplastic myelodysplastic syndrome Blood 1988 72: (Suppl. 1) 229a (Abstr.)

    Google Scholar 

  24. Biesma DH, van den Tweel JG, Verdonck LF . Immunosuppressive therapy for hypoplastic myelodysplastic syndrome Cancer 1997 79: 1548–1551

    Article  CAS  PubMed  Google Scholar 

  25. Molldrem J, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ . Antithymocyte globulin for patients with myelodysplastic syndrome Br J Haematol 1997 99: 699–705

    Article  CAS  PubMed  Google Scholar 

  26. Jonás¯ová A, Neuwirtová R, C¯ermák J, Vozobulová V, Mociková K, ŠiS¯ková M, Hochová I . Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow Br J Haematol 1998 100: 304–309

    Article  Google Scholar 

  27. Rosenfeld CS, Zeigler ZR, Shadduck RK, Nilsson B . Phase II study of roquinimex in myelodysplastic syndrome Am J Clin Oncol 1997 20: 189–192

    Article  CAS  PubMed  Google Scholar 

  28. Nand S, Stock W, Stiff P, Sosman J, Martone B, Radvany R . A phase II trial of interleukin-2 in myelodysplastic syndromes Br J Haematol 1998 101: 205–207

    Article  CAS  PubMed  Google Scholar 

  29. Saitoh K, Miura I, Takahashi N, Miura AB . Fluorescence in situ hybridization of progenitor cells obtained by fluorescence-activated cell sorting for the detection of cells affected by chromosome abnormality trisomy 8 in patients with myelodysplastic syndromes Blood 1998 92: 2886–2892

    CAS  PubMed  Google Scholar 

  30. Selleri C, Sato T, Anderson S, Young NS, Maciejewski JP . Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death J Cell Physiol 1995 165: 538–546

    Article  CAS  PubMed  Google Scholar 

  31. Nagafuji K, Shibuya T, Harada M, Mizuno S, Takenaka K, Miyamoto T, Okamura T, Gondo H, Niho Y . Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells Blood 1995 86: 883–889

    CAS  PubMed  Google Scholar 

  32. Maciejewski J, Selleri C, Anderson S, Young NS . Fas antigen expression on CD34+ human marrow cells is induced by interferon γ and tumor necrosis factor α and potentiates cytokine-mediated hematopoietic suppression in vitro Blood 1995 85: 3183–3190

    CAS  PubMed  Google Scholar 

  33. Zoumbos N, Symeonidis A, Kourakli A, Katevas P, Matsouka P, Perraki M, Georgoulias V . Increased levels of soluble interleukin-2 receptors and tumor necrosis factor in serum of patients with myelodysplastic syndromes Blood 1991 77: 413–414

    CAS  PubMed  Google Scholar 

  34. Verhoef GEG, De Schouwer P, Ceuppens JL, Van Damme J, Goossens W, Boogaerts MA . Measurement of serum cytokine levels in patients with myelodysplastic syndromes Leukemia 1992 12: 1268–1272

    Google Scholar 

  35. Stasi R, Brunetti M, Bussa S, Conforti M, Martin LS, Presa ML, Bianchi M, Parma A, Pagano A . Serum levels of tumour necrosis factor-α predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome Clin Lab Haematol 1997 19: 197–201

    Article  CAS  PubMed  Google Scholar 

  36. Koike M, Ishiyama T, Tomoyasu S, Tsuruoka N . Spontaneous cytokine overproduction by peripheral blood mononuclear cells from patients with myelodysplastic syndromes and aplastic anemia Leukemia Res 1995 19: 639–644

    Article  CAS  Google Scholar 

  37. Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahaski M, Tanizawa T, Kamiyama R, Hirokawa K . Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes Leukemia 1997 11: 2049–2054

    Article  CAS  PubMed  Google Scholar 

  38. Kitagawa M, Kamiyama R, Kasuga T . Increase in number of bone marrow macrophages in patients with myelodysplastic syndromes Eur J Haematol 1993 51: 56–58

    Article  CAS  PubMed  Google Scholar 

  39. Shetty V, Mundle S, Alvi S, Showel M, Broady-Robinson L, Dar S, Borok R, Showel J, Gregory S, Rifkin S, Gezer S, Parcharidou A, Venugopal P, Shah R, Hernandez B, Klein M, Alston D, Robin E, Dominquez C, Raza A . Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes Leukemia Res 1996 20: 891–900

    Article  CAS  Google Scholar 

  40. Janowska-Wieczorek A, Belch AR, Jacobs A, Bowen D, Padua RA, Paietta E, Stanley ER . Increased circulating colony-stimulating factor-1 in patients with preleukemia, leukemia, and lymphoid malignancies Blood 1991 77: 1796–1803

    CAS  PubMed  Google Scholar 

  41. Tobal K, Pagliuca A, Bhatt B, Bailey N, Layton DM, Mufti GJ . Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia Leukemia 1990 4: 486–489

    CAS  PubMed  Google Scholar 

  42. Gersuk GM, Beckham C, Loken MR, Kiener P, Anderson JE, Farrand A, Trout AB, Ledbetter JA, Deeg HJ . A role for tumour necrosis factor-alpha, Fas, and Fas-Ligand in marrow failure associated with myelodysplastic syndrome Br J Haematol 1998 103: 176–188

    Article  CAS  PubMed  Google Scholar 

  43. Ganser A, Ottmann OG, Seipelt G, Lindemann A, Hess U, Geissler G, Maurer A, Frisch J, Schulz G, Mertelsmann R, Hoelzer D . Effect of long-term treatment with recombinant human interleukin-3 in patients with myelodysplastic syndromes Leukemia 1993 7: 696–701

    CAS  PubMed  Google Scholar 

  44. Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L, Parcharidou A, Dar S, Venugopal P, Borok R, Gezer S, Showel J, Loew J, Robin E, Rifkin S, Alston D, Hernandez B, Shah R, Kaizer H, Gregory S . Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines Int J Hematol 1996 63: 265–278

    Article  CAS  PubMed  Google Scholar 

  45. Peddie CM, Wolf CR, McLellan LI, Collins AR, Bowen DT . Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-α concentration Br J Haematol 1997 99: 625–631

    Article  CAS  PubMed  Google Scholar 

  46. Nemunaitis J, Rosenfeld C, Getty L, Boegel F, Meyer W, Jennings LW, Zeigler Z, Shadduck R . Pentoxifylline and ciprofloxacin in patients with myelodysplastic syndrome Am J Clin Oncol 1995 18: 189–193

    Article  CAS  PubMed  Google Scholar 

  47. Raza A, Gezer S, Venugopal P, Kaizer H, Hines C, Thomas R, Alvi S, Mundle S, Shetty V, Borok R, Lowe J, Reza S, Robin EL, Rifkin SD, Alston D, Hernandez B, Shah R, Hsu WT, Dar S, Gregory SA . Hematopoietic and cytogenetic responses to novel anti-cytokine therapy in myelodysplastic syndromes (MDS) Proc ASCO 1997 16: 7a (Abstr.)

    Google Scholar 

  48. Hattori K, Hirano T, Miyajima H, Yamakawa N, Tateno M, Oshimi K, Kayagaki N, Yagita H, Okumura K . Differential effects of anti-Fas ligand and anti-tumor necrosis factor α antibodies on acute graft-versus-host disease pathologies Blood 1998 91: 4051–4055

    CAS  PubMed  Google Scholar 

  49. Nisticò A, Young NS . Gamma-interferon gene expression in the bone marrow of patients with aplastic anemia Ann Intern Med 1994 120: 463–469

    Article  PubMed  Google Scholar 

  50. Mundle SD, Venugopal P, Cartlidge JD, Pandav DV, Broday-Robinson L, Gezer S, Robin EL, Rifkin SR, Klein M, Alston DE, Hernandez BM, Rosi D, Alvi S, Shetty VT, Gregory SA, Raza A . Indication of an involvement of interleukin-1β converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes Blood 1996 88: 2640–2647

    CAS  PubMed  Google Scholar 

  51. Wetzler M, Kurzrock R, Estrov Z, Estey E, Talpaz M . Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia Leukemia Res 1995 19: 23–34

    Article  CAS  Google Scholar 

  52. Holmberg L, Seidel K, Leisenring W, Torok-Storb B . Cytokine production by long-term marrow cultures established from myelodysplastic patients Exp Hematol 1994 22: 741 (Abstr.)

    Google Scholar 

  53. Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R, Rifkin S, Iftikhar A, Shetty V, Parcharidou A, Loew J, Marcus B, Khan Z, Chaney C, Showel J, Gregory S, Preisler H . Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes Blood 1995 86: 268–276

    CAS  PubMed  Google Scholar 

  54. Rajapaksa R, Ginzton N, Rott LS, Greenberg PL . Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells Blood 1996 88: 4275–4287

    CAS  PubMed  Google Scholar 

  55. Bouscary D, De Vos J, Guesnu M, Jondeau K, Viguier F, Melle J, Picard F, Dreyfus F, Fontenay-Roupie M . Fas/Apo-1(CD95) expression and apoptosis in patients with myelodysplastic syndromes Leukemia 1997 11: 839–845

    Article  CAS  PubMed  Google Scholar 

  56. Parker JE, Mufti GJ . Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes Br J Haematol 1998 101: 220–230

    Article  CAS  PubMed  Google Scholar 

  57. Irvine AE, Magill MK, Somerville LE, McMullin MF . Spontaneous intramedullary apoptosis is present in disorders other than myelodysplasia Exp Hematol 1998 26: 435–439

    CAS  PubMed  Google Scholar 

  58. Bogdanović AD, Trpinac DP, Janoković GM, Bumbasirević V Z, Obradović M, Colović MD . Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment Leukemia 1997 11: 656–659

    Article  PubMed  Google Scholar 

  59. Gupta P, Niehans GA, LeRoy SC, Gupta K, Morrison VA, Schultz C, Knapp DJ, Kratzke RA . Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival Leukemia 1999 13: 44–53

    Article  CAS  PubMed  Google Scholar 

  60. Kitagawa M, Yamaguchi S, Takahaski M, Tanizawa T, Hirokawa K, Kamiyama R . Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia Leukemia 1998 12: 486–492

    Article  CAS  PubMed  Google Scholar 

  61. Davis RE, Greenberg PL . Bcl-2 expression by myeloid precursors in myelodysplastic syndrome: relation to progression Leukemia Res 1998 22: 767–777

    Article  CAS  Google Scholar 

  62. Mundle S, Mativi BY, Bagai K, Feldman G, Cheema G, Gautam U, Reza S, Cartlidge J, Venugopal P, Shetty V, Gregory SA, Raza A . A possible link of tumor necrosis factor a (TNFa) with down-regulation of Fas-associated phosphatase-1 (fap-1) and activation of Fas-mediated apoptosis in myelodysplasia J Clin Oncol 1999 18: 22a (Abstr.)

    Google Scholar 

  63. Klimecki W, Heaton R, Gibson BG, List AF . Amifostine suppresses apoptosis in myelodysplastic CD34+ cells and promotes progenitor cell growth via polyamine-like effects Blood 1997 90: (Suppl. 1) 520a (Abstr.)

    Google Scholar 

  64. List AF, Brasfield F, Heaton R, Glinsmann-Gibson B, Crook L, Taetle R, Capizzi R . Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome Blood 1997 90: 3364–3369

    CAS  PubMed  Google Scholar 

  65. Bowen DT, Denzlinger C, Brugger W, Culligan D, Gelly K, Adlakha S, Groves M, Hepurn M, Kanz L . Poor response rate to a continuous schedule of amifostine therapy for ‘low/intermediate risk’ myelodysplastic patients Br J Haematol 1998 103: 785–787

    Article  CAS  PubMed  Google Scholar 

  66. Garcia-Bermejo L, Pérez C, Vilaboa N, de Blas E, Aller P . cAMP increasing agents attenuate the generation of apoptosis by etoposide in promonocytic leukemia cells J Cell Sci 1998 111: 637–644

    CAS  PubMed  Google Scholar 

  67. Caligo MA, Cipollini G, Petrini M, Valentini P, Bevilacqua G . Down regulation of NM23.H1, NM23.H2 and c-myc genes during differentiation induced by 1,25 dihydroxyvitamin D3 Leukemia Res 1996 20: 161–167

    Article  CAS  Google Scholar 

  68. Calabretta B, Skorski T . Targeting c-myc in leukemia Anticancer Drug Des 1997 12: 373–381

    CAS  PubMed  Google Scholar 

  69. Greenberg PL . Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes Semin Hematol 1996 33: 163–175

    CAS  PubMed  Google Scholar 

  70. Aul C, Gattermann N, Schneider W . Comparison of in vitro growth characteristics of blast cell progenitors (CFU-L) in patients with myelodysplastic syndromes and acute myeloid leukemia Blood 1992 80: 625–633

    CAS  PubMed  Google Scholar 

  71. Sawada K, Sato N, Notoya A, Tarumi T, Hirayama S, Takano H, Koizumi K, Yasukouchi T, Yamaguchi M, Koike T . Proliferation and differentiation of myelodysplastic CD34+ cells: phenotypic subpopulations of marrow CD34+ cells Blood 1995 85: 194–202

    CAS  PubMed  Google Scholar 

  72. Santini V, Ferrini PR . Differentiation therapy of myelodysplastic syndromes: fact or fiction? Br J Haematol 1998 102: 1124–1138

    Article  CAS  PubMed  Google Scholar 

  73. Mellibovsky L, Diez A, Pérez-Vila E, Serrano S, Nacher M, Aubía J, Supervía A, Recker RR . Vitamin D treatment in myelodysplastic syndromes Br J Haematol 1998 100: 516–520

    Article  CAS  PubMed  Google Scholar 

  74. Howard MR, Bond LR . Calcitriol in myelodysplastic syndromes Br J Haematol 1999 106: 569–574

    Article  Google Scholar 

  75. Bowen D, Yancik S, Bennett L, Culligan D, Resser K . Serum stem cell factor concentration in patients with myelodysplastic syndromes Br J Haematol 1993 85: 63–66

    Article  CAS  PubMed  Google Scholar 

  76. Zwierzina H, Schöllenberger S, Herold M, Schmalzl F, Besemer J . Endogenous serum levels and surface receptor expression of GM-CSF and IL-3 in patients with myelodysplastic syndromes Leukemia Res 1992 16: 1181–1186

    Article  CAS  Google Scholar 

  77. Gidáli J, Fehér I, Hollán S . Blast colony forming cell-binding capacity of bone marrow stroma from myelodysplastic patients Stem Cells 1996 14: 577–583

    Article  PubMed  Google Scholar 

  78. Tennant GB, Truran LN, Kell WJ, Burnett AK . Myelodysplastic bone marrow stroma is defective in its ability to sustain normal stem cell growth Blood 1997 90: (Suppl. 1) 582a (Abstr.)

    Google Scholar 

  79. Greenberg PL, Mackichan ML, Negrin R, Renick M, Ginzton N . Production of granulocyte colony stimulating factor (G-CSF) by normal and myelodysplastic syndrome (MDS) peripheral blood (PB) cells Blood 1990 76:: (Suppl. 1) 146a (Abstr.)

  80. Visani G, Zauli G, Tosi P, Fogli M, Cenacchi A, Finelli C, Gamberi B, Ottaviani E, Manfoi S, Tura S . Impairment of GM-CSF production in myelodysplastic syndromes Br J Haematol 1993 84: 227–231

    Article  CAS  PubMed  Google Scholar 

  81. Ganser A, Karthaus M . Clinical use of hematopoietic growth factors in the myelodysplastic syndromes Leuk Lymphoma 1997 26: (Suppl.1) 13–29

    Article  CAS  PubMed  Google Scholar 

  82. Mencoboni M, Castello G, Lerza R, Haupt E, Ballarine P, Cerruti A, Bogliolo G, Pannacciulli I . Production of tumor necrosis factor and granulocyte colony stimulating factor by bone marrow accessory cells in myelodysplastic patients Eur J Haematol 1996 56: 148–152

    Article  CAS  PubMed  Google Scholar 

  83. Cortelezzi A, Cattaneo C, Cristiani S, Sarina B, Pomati M, Silvestris I, Ibatici A, Maiolo AT . Low plasma stem cell factor levels correlate with in vitro leukemic growth in myelodysplastic syndromes Leukemia Res 1999 23: 271–275

    Article  CAS  Google Scholar 

  84. Merchav S, Nagler A, Fleischer-Kurtz G, Tatarsky I . Regulatory abnormalities in the marrow of patients with myelodysplastic syndromes Br J Haematol 1989 73: 158–164

    Article  CAS  PubMed  Google Scholar 

  85. Zwierzina H, Anderson JE, Rollinger-Holzinger I, Torok-Storb B, Nuessler V, Lyman SD . Endogenous FLT-3 ligand serum levels are associated with disease stage in patients with myelodysplastic syndromes Leukemia 1999 13: 553–557

    Article  CAS  PubMed  Google Scholar 

  86. Ohyashiki JH, Iwama H, Yahata N, Ando K, Hayashi, Shay JW, Ohyashiki K . Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes Clin Cancer Res 1999 5: 1155–1160

    CAS  PubMed  Google Scholar 

  87. Boultwood J, Fidler C, Kusec R, Rack K, Elliott JW, Atoyebi O, Chapman R, Oscier DG, Wainscoat JS . Telomere length in myelodysplastic syndromes Am J Hematol 1997 56: 266–271

    Article  CAS  PubMed  Google Scholar 

  88. Sharma S, Raymond E, Soda H, Sun D, Hilsenbeck SG, Sharma A, Izbicka E, Windle B, Von Hoff DD . Preclinical and clinical strategies for development of telomerase and telomere inhibitors Ann Oncol 1997 8: 1063–1074

    Article  CAS  PubMed  Google Scholar 

  89. Kirsch DG, Kastan MB . Tumor-suppressor p53: implications for tumor development and prognosis J Clin Oncol 1998 16: 3158–3168

    Article  CAS  PubMed  Google Scholar 

  90. Sugimoto K, Hirano N, Toyoshima H, Chiba S, Mano H, Takaku F, Yazaki Y, Hirai H . Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia Blood 1993 81: 3022–3026

    CAS  PubMed  Google Scholar 

  91. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux . p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies Blood 1994 84: 3148–3157

    CAS  PubMed  Google Scholar 

  92. Mitani K, Hangaishi A, Imamura N, Miyagawa K, Ogawa S, Kanda Y, Yazaki Y, Hirai H . No concomitant occurrence of the N-ras and p53 gene mutations in myelodysplastic syndromes Leukemia 1997 11: 863–865

    Article  CAS  PubMed  Google Scholar 

  93. Adamson DJA, Dawson AA, Bennett B, King DJ, Haites NE . p53 mutation in the myelodysplastic syndromes Br J Haematol 1995 89: 61–66

    Article  CAS  PubMed  Google Scholar 

  94. Preudhomme C, Fenaux P . The clinical significance of mutations of the p53 tumour suppressor gene in haematological malignancies Br J Haematol 1997 98: 502–511

    Article  CAS  PubMed  Google Scholar 

  95. Nielsen LL, Maneval DC . p53 tumor suppressor gene therapy for cancer Cancer Gene Ther 1998 5: 52–63

    CAS  PubMed  Google Scholar 

  96. Bishop MR, Iversen PL, Bayever E, Sharp JG, Greiner TC, Copple BL, Ruddon R, Zon G, Spinolo J, Arneson M, Armitage JO, Kessinger A . Phase I trial of an antisense oligonucleotide OL(1) p53 in hematologic malignancies J Clin Oncol 1996 14: 1320–1326

    Article  CAS  PubMed  Google Scholar 

  97. Masuya M, Kita K, Shimizu N, Ohishi K, Kataya N, Sekine T, Otsuji A, Miwa H, Shirakaw S . Biologic characteristics of acute leukemia after myelodysplastic syndrome Blood 1993 81: 3388–3394

    CAS  PubMed  Google Scholar 

  98. Uchida T, Kinoshita T, Nagai H, Nakahara Y, Saito H, Hotta T, Murate T . Hypermethylation of the p15INK4B gene in myelodysplastic syndromes Blood 1997 90: 1403–1409

    CAS  PubMed  Google Scholar 

  99. Quesnel B, Guillerm G, Vereecque R, Wattel E, Preudhomme C, Bauters F, Vanrumbeke M, Fenaux P . Methylation of the p15INK4B gene in myelodysplastic syndromes is frequent and acquired during disease progression Blood 1998 91: 2985–2990

    CAS  PubMed  Google Scholar 

  100. Bender CM, Zingg JM, Jones PA . DNA methylation as a target for drug design Pharm Res 1998 15: 175–187

    Article  CAS  PubMed  Google Scholar 

  101. Momparler RL, Cote S, Eliopoulos N . Pharmacological approach for optimization of the dose schedule of 5-Aza-2′-deoxycytidine (Decitabine) for the therapy of leukemia Leukemia 1997 11: 175–180

    Article  CAS  PubMed  Google Scholar 

  102. Silverman LR, Demakos EP, Peterson B, Odchimar-Reissig R, Nelson D, Kornblith AB, Stone R, Holland JC, Powell BL, DeCatro C, Ellerton J, Larson RA, Schiffer CA, Holland JF . A randomized controlled trial of subcutaneous azacitidine (AZA C) in patients with the myelodysplastic syndrome (MDS): a study of the Cancer and Leukemia Group B (CALGB) Proc ASCO 1998 17: 14a (Abstr.)

    Google Scholar 

  103. Herman JG, Jen J, Merlo A, Baylin SB . Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B1 Cancer Res 1996 56: 722–727

    CAS  PubMed  Google Scholar 

  104. Wijermans PW, Krulder JWM, Huijgens PC, Neve P . Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome Leukemia 1997 11: 1–5

    Article  CAS  PubMed  Google Scholar 

  105. Lübbert M, Haak HL, Kunzmann R, Danzer-Driessen S, Verhoef G, Mertelsmann R, Wijermans P . Cytogenetic response to low-dose 5-Aza-2′-deoxycytidine (DAC) in poor-risk myelodysplastic syndromes (MDS)–phase II study results Blood 1997 90: 582a (Abstr.)

    Google Scholar 

  106. Ball SE, Gibson FM, Rizzo S, Tooze JA, March JCW, Gordon-Smith EC . Progressive telomere shortening in aplastic anemia Blood 1998 91: 3582–3592

    CAS  PubMed  Google Scholar 

  107. Nakao S, Yamaguchi M, Shiobara S, Yokoi T, Miyawaki T, Taniguichi T, Matsuda T . Interferon-γ gene expression in unstimulated bone marrow mononuclear cells predicts a good response to cyclosporine therapy in aplastic anaemia Blood 1992 79: 2532–2535

    CAS  PubMed  Google Scholar 

  108. Hinterberger W, Adolf G, Bettelheim P, Geissier K, Huber C, Irschick E, Kalhs P, Köller U, Lechner K, Meister B, Woloszcszuk W . Lymphokine overproduction in severe aplastic anemia is not related to blood transfusions Blood 1989 74: 2713–2717

    CAS  PubMed  Google Scholar 

  109. Young NS, Maciejewski J . The pathophysiology of acquiredaplastic anemia New Engl J Med 1997 336: 1365–1372

    Article  CAS  PubMed  Google Scholar 

  110. Philpott NJ, Scopes J, Marsh JC, Gordon-Smith EC, Gibson FM . Increased apoptosis in aplastic anemia bone marrow progenitor cells: possible pathophysiologic significance Exp Hematol 1995 23: 1642–1648

    CAS  PubMed  Google Scholar 

  111. Callera F, Falcao RP . Increased apoptotic cells in bone marrow biopsies from patients with aplastic anaemia Br J Haematol 1997 98: 18–20

    Article  CAS  PubMed  Google Scholar 

  112. Raghavachar A, Janssen JWG, Schrezenmeier H, Wagner B, Bartram CR, Schulz AS, Hein C, Cowling G, Mubarik A, Testa NG, Dexter TM, Hows JM, Marsh JCW . Clonal hematopoiesis as defined by polymorphic X-linked loci occurs infrequently inaplastic anemia Blood 1995 86: 2938–2947

    CAS  PubMed  Google Scholar 

  113. Kojima S, Matsuyama T, Kodera Y . Hematopoietic growth factors released by marrow stromal cells from patients with aplasticanemia Blood 1992 79: 2256–2261

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Texas Oncology, PA, Dallas, TX, USA

    C Rosenfeld

  2. University of Arizona Cancer Center, Tucson, AZ, USA

    A List

Authors
  1. C Rosenfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A List
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosenfeld, C., List, A. A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. Leukemia 14, 2–8 (2000). https://doi.org/10.1038/sj.leu.2401618

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401618

Keywords

This article is cited by

Search

Advanced search

Quick links